Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor

Primary Objective:

To describe the incidence and characteristics of, and change in, chronic neuropathy symptoms related to cisplatin, using the EORTC CIPN-20 instrument

Procedures:

The EORTC QLQ-CIPN20 questionnaire will be completed on day one of each cycle of chemotherapy, once every three weeks (+/-7 days) and once every 2 months (+/- 30 days) from the last dose of chemotherapy. Patients will be asked to complete the questionnaire in clinic during their routine visits.

As part of this study, a DNA blood sample will be collected and stored with the Indiana Biobank on Day 1 of Cycle 1.

Inclusion criteria

• 15 years of age or older at the time of informed consent
• Have a confirmed pathologic and/or by tumor marker diagnosis of testicular or extragonadal germ cell cancer.
• Provide written informed consent and assent (if applicable).
• Ability to complete questionnaire(s) in English by themselves or with assistance.
• Willing to provide a 10 mL blood sample for future DNA testing
• Planning to receive at least 3 cycles of cisplatin (20 mg/m2/d for 5 days) based chemotherapy.
• Must agree to continued clinical follow-up at the study cancer center.

Exclusion criteria

• Diagnosis (current or previous) of peripheral neuropathy (from diabetes or other causes).
• Previous exposure to neurotoxic chemotherapy drugs including taxanes, platinum agents, vinca alkaloids, or epothilones.
• Salvage chemotherapy treatment or bone marrow transplant. Salvage chemotherapy is defined as any treatment after relapse of the disease following initial chemotherapy treatment.